[World Report] “It's not about us anymore”: after the Le Scouarnec case
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01634-4/fulltext?rss=yes

Joël Le Scouarnec sexually assaulted hundreds of patients in his care. His victims are now calling for institutional changes in the wake of his conviction. Marianne Guenot reports.

[Articles] Safety and efficacy of MCO-010 optogenetic therapy in patients with Stargardt disease in USA (STARLIGHT): an open-label multi-center Ph2 trial
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00362-1/fulltext?rss=yes

MCO-010 optogenetic phase 2 results support further investigation for treatment SD. To our knowledge, this is the first report of improving on(eye)-chart vision of SD participants utilizing optogenetics.

[Articles] Radiation dose escalation in locally advanced oesophageal cancer: a systematic review and hierarchical Bayesian meta-analysis
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00364-5/fulltext?rss=yes

Radiation dose escalation improves locoregional control and may enhance OS in SqCC, particularly in Asian populations, highlighting the need for histology- and region-specific therapeutic strategies. The choice of chemotherapy regimen may affect the interpretation of survival effects associated with high-dose. Furthermore, the genomic correlates of radiosensitivity and immune activation suggest potential for biologically guided dose personalization and combination with immunotherapy.

[Department of Error] Department of Error
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01638-1/fulltext?rss=yes

Early Breast Cancer Trialists' Collaborative Group. Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy. Lancet 2025; 406: 603–14— In figure 4 of this Article, the subheadings were incorrectly removed. In figure 6, the first column heading should have read “Events/woman-years” and the last column heading should have read “Ratio of annual event rates (95% CI)”.

[Articles] Safety of budesonide/glycopyrronium/formoterol fumarate dihydrate delivered by HFO-1234ze versus HFA-134a in chronic obstructive pulmonary disease: a phase 3, multi-site, randomised, double-blind, parallel-group, active-comparator study
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00334-7/fulltext?rss=yes

These findings support the potential for HFO-1234ze to replace HFA-134a in pMDIs containing BGF, which could be evaluated further in a real-world setting.